Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients globally; U.S. ...
View HTML
Toggle Summary RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204
The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease Follows recent agreement with Cosmo for expansion of opaganib manufacturing capacity for COVID-19 TEL AVIV, Israel and RALEIGH, ...
View HTML
Toggle Summary RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
- The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalization - the vast majority of patients - RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in ...
View HTML
Toggle Summary RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences
TEL AVIV, Israel and RALEIGH, N.C. , Feb. 9, 2021 /PRNewswire/ --   RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in February:     SVB Leerink 10 th Annual Global ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
Following interim review of unblinded safety and efficacy data, independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 Opaganib targets a human cell component involved in viral replication and is therefore expected to ...
View HTML
Toggle Summary RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study, progress with the ongoing global Phase 2/3 study, and amid the urgent need to address emerging viral strains TEL AVIV, Israel and RALEIGH, N.C. ...
View HTML
Toggle Summary RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten offering of 3,188,776 American Depositary Shares (ADSs) ...
View HTML
Toggle Summary RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and ...
View HTML
Toggle Summary RedHill Biopharma Announces $10 Million Bought Deal Offering
TEL AVIV, Israel and RALEIGH, N.C. , Jan. 11, 2021 /PRNewswire/ --  RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. ...
View HTML
Toggle Summary RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D
TEL AVIV, Israel and RALEIGH, N.C ,, Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had successfully completed ...
View HTML